Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Blood

Volumn 125, Issue 19, 2015, Pages 3024-3031

  McCurdy, Shannon R ^a   Kanakry, Jennifer A ^a   Showel, Margaret M ^a   Tsai, Hua Ling ^a   Bolaños Meade, Javier ^a   Rosner, Gary L ^a   Kanakry, Christopher G ^a   Perica, Karlo ^a   Symons, Heather J ^a   Brodsky, Robert A ^a   Gladstone, Douglas E ^a   Huff, Carol Ann ^a   Pratz, Keith W ^a   Prince, Gabrielle T ^a   Dezern, Amy E ^a   Gojo, Ivana ^a   Matsui, William H ^a   Borrello, Ivan ^a   McDevitt, Michael A ^a   Swinnen, Lode J ^a   Smith, B Douglas ^a   Levis, Mark J ^a   Ambinder, Richard F ^a   Luznik, Leo ^a   Jones, Richard J ^a   Fuchs, Ephraim J ^a   Kasamon, Yvette L ^a   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; TACROLIMUS; ALKYLATING AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HLA SYSTEM; HODGKIN DISEASE; HUMAN; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPROLIFERATIVE NEOPLASM; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; T LYMPHOCYTE; TREATMENT OUTCOME; ADOLESCENT; ALLOTRANSPLANTATION; CANCER STAGING; DOSE RESPONSE; FOLLOW UP; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84929208047     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-623991     Document Type: Article

References (35)

1. Brunstein CG, Fuchs EJ, Carter SL, et al Blood and Marrow Transplant Clinical Trials Network. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282-288.
2. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313(13):765-771.
3. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92(10):3515-3520.
4. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99(11):4200-4206.
5. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15(5):1767-1777.
6. Bastien JP, Roy J, Roy DC. Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation. Semin Oncol. 2012;39(6):674-682.
7. Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(12):1835-1844.
8. Jones RJ. Haploidentical transplantation: repurposing cyclophosphamide. Biol Blood Marrow Transplant. 2012;18(12):1771-1772.
9. Luznik L, Bolaños-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115(16):3224-3230.
10. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650.
11. Raiola A, Dominietto A, Varaldo R, et al. Unmanipulated haploidentical BMT following nonmyeloablative conditioning and posttransplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant. 2014;49(2):190-194.
12. Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012;18(12):1859-1866.
13. Kanakry CG, O'Donnell PV, Furlong T, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014;32(31):3497-3505.
14. Sayer HG, Kröger M, Beyer J, et al Cooperative German Transplant Study Group. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant. 2003;31(12):1089-1095.
15. Armand P, Gibson CJ, Cutler C, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120(4):905-913.
16. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664-3671.
17. Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010;16(4):482-489.
18. Hallek M, Cheson BD, Catovsky D, et al International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
19. Cheson BD, Pfistner B, Juweid ME, et al International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
20. Cheson BD, Bennett JM, Kopecky KJ, et al International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
21. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
22. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
23. Zhou B, Latouche A, Rocha V, Fine J. Competing risks regression for stratified data. Biometrics. 2011;67(2):661-670.
24. Ihaka R, Gentleman RR. A language for data analysis and graphics. J Comput Graph Stat. 1996;5:299-314.
25. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
26. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
27. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32(29):3249-3256.
28. Dehn J, Buck K, Maiers M, et al. 8/8 and 10/10 high-resolution match rate for the Be The Match unrelated donor registry. Biol Blood Marrow Transplant. 2015;21(1):137-141.
29. Ho VT, Kim HT, Aldridge J, et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(8):1196-1204.
30. Sabry W, Le Blanc R, Labbé AC, et al. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant. 2009;15(8):919-929.
31. Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013;31(12):1530-1538.
32. Versluis J, Labopin M, Niederwieser D, et al. Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia. 2015;29(1):51-57.
33. Chen YB, Li S, Lane AA, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014;20(12):2042-2048.
34. Symons HJ, Chen A, Gamper C, et al. Haploidentical BMT using fully myeloablative conditioning, T cell replete bone marrow grafts, and post-transplant cyclophosphamide (PT/Cy) has limited toxicity and promising efficacy in largest reported experience with high risk hematologic malignancies [abstract]. Biol Blood Marrow Transplant. 2015;21(2):S29.
35. A multi-center, phase III, randomized trial of reduced intensity (RIC) conditioning and transplantation of double unrelated umbilical cord blood (dUCB) versus HLA-haploidentical related bone marrow (Haplo-BM) for patients with hematologic malignancies (BMT CTN #1101). https://www.clinicaltrials.gov/ct2/show/NCT01597778. Accessed December 15, 2014.